Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Status:
Completed
Trial end date:
2017-09-28
Target enrollment:
Participant gender:
Summary
This trial will evaluate the efficacy and the safety of a strategy of allogeneic stem cell
transplantation including Rituximab in the conditioning regimen for the treatment of relapsed
follicular lymphoma. The rationale for using Rituximab relies on a better control of the
disease and a better prophylaxis of the graft versus host disease.